Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current therapy for Wilms' tumor.

Monika L Metzger1, Jeffrey S Dome

  • 1Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105-2794, USA.

The Oncologist
|November 30, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

​EuroNet-PHL-LP1: Complete resection or low-dose chemo for pediatric low-risk nodular lymphocyte-predominant Hodgkin lymphoma.

Blood advances·2026
Same author

Integrated Molecular, Genomic, and Clinical Characterization of Pediatric and Adolescent Translocation Renal Cell Carcinoma: A Report from the Children's Oncology Group.

Biomedicines·2026
Same author

Treatment of extracranial rhabdoid tumor with intensive ifosfamide-containing chemotherapy regimens.

Frontiers in oncology·2026
Same author

Estimation of Detailed Cardiac Doses for Pediatric Radiation Therapy Patients in National Wilms Tumor Study.

International journal of radiation oncology, biology, physics·2026
Same author

Dose-dense chemotherapy enables elimination of RT for the majority of low-risk pediatric Hodgkin lymphomas: PHC study HOD08.

Blood·2026
Same author

Relapsed rhabdoid tumours and other non-nephroblastoma childhood and adolescent kidney tumours: perspectives from the HARMONICA collaboration.

Nature reviews. Urology·2026
Same journal

The Impact of Relative Dose Intensity on pCR in Neoadjuvant Chemotherapy of Muscle-Invasive Urothelial Cancer: a Multicentre Retrospective Study.

The oncologist·2026
Same journal

Prevalence, treatment and survival of Malignant Peripheral Nerve Sheath Tumor in the Danish neurofibromatosis type 1 population.

The oncologist·2026
Same journal

Molecular Tumor Board-Guided Osimertinib Therapy in EGFR L858R/Q701L-Mutant Lung Adenocarcinoma Supported by Functional Validation.

The oncologist·2026
Same journal

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

The oncologist·2026
Same journal

Divergent Biology and Outcomes of Somatic Transformations in Germ Cell Tumors.

The oncologist·2026
Same journal

Modernizing Disease Assessment in Prostate Cancer Trials: The Prostate Cancer Working Group 4 Framework.

The oncologist·2026
See all related articles

Adjuvant chemotherapy has significantly improved outcomes for Wilms tumor, a rare kidney cancer in children. Current research aims to reduce treatment for low-risk cases and intensify it for high-risk Wilms tumors.

Area of Science:

  • Pediatric Oncology
  • Medical Oncology
  • Cancer Research

Background:

  • Wilms tumor was the first solid malignancy to establish the value of adjuvant chemotherapy.
  • Multimodality treatment has improved outcomes from 30% to over 85%.

Purpose of the Study:

  • To reduce therapy for children with low-risk Wilms tumors, minimizing toxicities.
  • To augment therapy for high-risk Wilms tumors, including bilateral, anaplastic, and recurrent favorable histology types.

Main Methods:

  • Review of historical treatment data and outcomes.
  • Analysis of current clinical trial strategies for Wilms tumor.
  • Comparison of up-front nephrectomy versus preoperative chemotherapy approaches.

Main Results:

Related Experiment Videos

  • Excellent outcomes reported for both up-front nephrectomy and preoperative chemotherapy.
  • Significant improvement in survival rates for Wilms tumor patients over decades.

Conclusions:

  • Ongoing clinical trials focus on risk-stratified treatment for Wilms tumor.
  • Efforts are directed towards minimizing treatment burden in low-risk patients while optimizing therapy for high-risk cases.